Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
BOTHELL, Wash., April 30, 2018 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will report its first quarter 2018 financial and operating results after the close of U.S. financial markets on Tuesday, May 8, 2018. Alder management will host a conference call and live audio webcast with accompanying slides to discuss the results and provide a general business update at 5:00 p.m. ET the same day.
The live call may be accessed by dialing (877) 430-4657 for domestic callers or (484) 756-4339 for international callers and providing conference ID number 1767109. The webcast and accompanying slides can be accessed from the Events & Presentations page in the Investors section of Alder's website at www.alderbio.com and will be available for replay following the call for at least 30 days.
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. Unlike other CGRP inhibitors, eptinezumab was specifically designed as an infusion therapy to address significant patient need. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, please visit www.alderbio.com.
Investor Relations Contacts:
Ashwin Agarwal
Vice President, Corporate Strategy
Alder Biopharmaceuticals, Inc.
425-408-8567
[email protected]
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Media Contact:
Andy Brimmer / Aura Reinhard / Trevor Gibbons
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
